Treatment of xanthoma disseminatum with cyclophosphamide.

Abstract

Xanthoma disseminatum is a rare non-Langerhans cell (class II) histiocytosis, which is often resistant to treatment. We describe an illustrative case with extensive mucocutaneous, ocular, laryngeal, pituitary and central nervous system involvement, which responded to treatment with cyclophosphamide. The presentation, course and treatment of the condition are reviewed. Many of the non-Langerhans cell histiocytoses represent a spectrum of diseases of dermal dendrocytes ranging from self-limiting and benign conditions to multisystem progressive diseases that respond poorly to treatment and severely impair quality of life. We suggest that chemotherapy should be considered at an early stage in the more aggressive subtypes of non-Langerhans cell histiocytoses.

• Authors: E D Seaton, G J Pillai, A C Chu
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 150 Issue 2 Pg. 346-9 (Feb 2004) ISSN: 0007-0963 [Print] England
• PMID: 14996108 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Cyclophosphamide

Topics

• Adolescent
• Antineoplastic Agents, Alkylating (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Humans
• Male
• Skin Neoplasms (drug therapy, pathology)
• Xanthomatosis (drug therapy, pathology)